Also, our recent investigation of patients with HT provided evidence that both -318C/T promoter and 49A/G exon 1 CTLA-4 gene single nucleotide polymorphisms (SNPs) were associated with higher thyroid autoantibody concentrations, confirming its important role in thyroid autoantibody production [6]. In the CTLA-4 gene additional polymorphisms were described, among which the CT60 SNP in the 3′-untranslated region was found to affect the efficiency of splicing with reduced production of soluble CTLA-4 [7]. In spite of being associated strongly with AITD [8], the influence of CT60 SNP on thyroid autoantibody production has not been determined until now. Therefore, the objective

of the present study was to evaluate the association of CT60 CTLA-4 SNP with thyroid autoantibody production in patients with two different forms of autoimmune thyroid VX-809 ic50 disease, HT and PPT. A total of 180 Caucasian patients from Slovenia were recruited consecutively, including 105 patients with HT and 75 patients with PPT. All patients were newly diagnosed and had been evaluated prior to initiation of treatment. Among HT patients, 96 females and nine males, aged between 17 and 83 (mean 51·1 ± 16·8) years, were investigated. The inclusion criteria were subclinical or clinical

and biochemical hypothyroidism, the presence of thyroid peroxidase antibodies and/or thyroglobulin antibodies Belinostat solubility dmso and characteristic hypoechoic thyroid ultrasound (US) pattern. In females with PPT, aged between 21 and 42 (mean, 30·4 ± 4·7) years, thyroid dysfunction occurred in the first year postpartum. Hyperthyroidism was diagnosed in patients with suppressed thyroid stimulating hormone (TSH) and normal or elevated free thyroid

hormones; the mean time from the delivery to diagnosis was 5·5 ± 2·2 months. Hypothyroidism was confirmed in patients with elevated TSH and normal or decreased free thyroid hormones; the mean time from the delivery to diagnosis was 7·1 ± 2·6 months. The patients presented with normal or hypoechoic US pattern, most of them were positive for thyroid peroxidase antibodies or thyroglobulin antibodies. Patients Morin Hydrate with positive TSH receptor stimulating antibodies, which are distinctive of Graves’ disease, were excluded from the study. In all patients, the data on family history of AITD and cigarette smoking were obtained. TSH was measured by commercially available chemiluminescent immunoassay kit (TSH-3; Siemens Medical Solutions Diagnostics, Tarrytown, NY, USA; reference range, 0·35–5·5 mU/l). Thyroid peroxidase antibodies and thyroglobulin antibodies were determined using commercially available enzyme-linked immunosorbent assay kit (ETI-AB-TPOK and ETI-AB-HTGK; Dia Sorin, Saluggia, Vercelli, Italy; positive value, above 15 U/ml and above 100 U/ml, respectively).